4/15
08:11 am
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at Needham & Company LLC from a "hold" rating to a "buy" rating. They now have a $138.00 price target on the stock.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at Needham & Company LLC from a "hold" rating to a "buy" rating. They now have a $138.00 price target on the stock.
4/14
04:01 pm
nbix
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results
Low
Report
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results
4/14
08:09 am
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at Royal Bank of Canada from a "sector perform" rating to an "outperform" rating. They now have a $137.00 price target on the stock.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at Royal Bank of Canada from a "sector perform" rating to an "outperform" rating. They now have a $137.00 price target on the stock.
4/4
10:45 am
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target lowered by analysts at UBS Group AG from $154.00 to $137.00. They now have a "buy" rating on the stock.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target lowered by analysts at UBS Group AG from $154.00 to $137.00. They now have a "buy" rating on the stock.
4/4
08:11 am
nbix
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer [Yahoo! Finance]
Low
Report
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer [Yahoo! Finance]
4/4
08:00 am
nbix
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
Medium
Report
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
3/31
08:49 am
nbix
Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia [Yahoo! Finance]
Low
Report
Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia [Yahoo! Finance]
3/31
08:30 am
nbix
Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia
Low
Report
Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia
3/26
08:39 am
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at JPMorgan Chase & Co. from $183.00 to $184.00. They now have an "overweight" rating on the stock.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at JPMorgan Chase & Co. from $183.00 to $184.00. They now have an "overweight" rating on the stock.
3/20
08:30 am
nbix
Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules
Low
Report
Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules
3/20
02:06 am
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
3/17
08:30 am
nbix
Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules
Low
Report
Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules
3/12
11:05 pm
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
3/11
04:42 pm
nbix
Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum [Yahoo! Finance]
Low
Report
Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum [Yahoo! Finance]
3/11
04:01 pm
nbix
Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum
Low
Report
Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum
3/7
12:54 pm
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $150.00 price target on the stock, down previously from $185.00.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $150.00 price target on the stock, down previously from $185.00.
3/5
09:06 am
nbix
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults [Yahoo! Finance]
Low
Report
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults [Yahoo! Finance]
3/5
08:30 am
nbix
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
Low
Report
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
2/27
04:26 pm
nbix
Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures [Yahoo! Financ
Low
Report
Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures [Yahoo! Financ
2/27
04:05 pm
nbix
Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures
Low
Report
Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures
2/25
04:01 pm
nbix
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March
Low
Report
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March
2/21
08:47 am
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $185.00 price target on the stock.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $185.00 price target on the stock.
2/21
08:13 am
nbix
Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program [Yahoo! Finance]
Low
Report
Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program [Yahoo! Finance]
2/21
08:00 am
nbix
Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program
Low
Report
Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program
2/18
04:21 pm
nbix
Neurocrine (NBIX): Among Top Insider Stock Buys And Sells In January [Yahoo! Finance]
Low
Report
Neurocrine (NBIX): Among Top Insider Stock Buys And Sells In January [Yahoo! Finance]